Corporate Banner
Satellite Banner
Technology Networks Header
Friday, November 21, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Single Copy qPCR-Based Detection of BRAF and KRAS Mutations
  Videos

Return

Single Copy qPCR-Based Detection of BRAF and KRAS Mutations
Swift Biosciences Inc

Vladimir Makarov, Chief Scientific Officer, Swift Biosciences Inc

Abstract
The development of highly sensitive genotyping assays that are suitable for clinical diagnostics opens new opportunities for the detection, assessment, and management of cancer.  Anticipated uses for these assays include profiling tissue biopsies, circulating tumor cells (CTCs), and detecting mutations in circulating cell-free nucleic acids.  Swift Biosciences™ has developed myT™ Primers which have unique structural and thermodynamic properties that make them highly sensitive to mismatch discrimination. A myT Primer assay for BRAF V600E/K mutations demonstrated single mutant copy sensitivity in a background of 14,000 wild-type genomic DNA copies. This assay also demonstrated high specificity as indicated by a low percentage (< 3%) of amplification events from 14,000 wild-type genomic copies. myT Primer assays are compatible with multiple qPCR instruments and reaction mixes.  myT Primer qPCR assays for seven common KRAS mutations demonstrated similar sensitivity and specificity. When compared to a leading commercially available KRAS mutation qPCR test kit, several orders of improved specificity were observed. The extreme selectivity of myT Primer assays will be especially useful for detection of mutations present at ultra-low copy number and for genotyping difficult samples such as needle biopsies, CTCs, and serum, resulting in better detection, evaluation, and monitoring of cancer.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
New Test Developed at Dana-Farber/Brigham and Women's Cancer Center
Rapid Heme Panel - A high-tech genetic test that speeds treatment decisions for blood cancer patients.
Urgent Need for Fast Dx to Help Tackle Antibiotic Resistance
£10 million Longitude Prize for an accurate, rapid, cost-effective and easy-to-use point-of-need diagnostic test for bacterial infections.
Test Developed To Rapidly Diagnose Bloodstream Infection
New technology can detect bacterial invaders with unprecedented speed and sensitivity.
Classification of Gene Mutations in Neuroblastoma
Penn Medicine and CHOP experts define riskier mutations in neuroblastoma, setting stage for clinical trial.
New Genetic Cause of Epilepsy Identified
San Diego girl improves after discovery of DNA mutation tied to potassium regulation.
Cancer Cell Fingerprints in the Blood May Speed up Childhood Cancer Diagnosis
Researchers found unique molecular fingerprints for 11 types of children’s tumours, to develop blood tests to diagnose these cancers.
Blood Test Developed to Diagnose Early Onset Alzheimer’s Disease
New blood-test could predict a person’s risk of developing AD much earlier than is currently possible.
Genome Sequenced of Enterovirus D68
Virus has spread rapidly causing severe respiratory illness in young children, with some patients requiring hospitalization.
Rapid Test To Diagnose Severe Sepsis
A test could help doctors diagnose sepsis and begin treatment earlier.
IDT Shares Tips for Optimizing Target Capture
The article discusses improved target capture methods for increasing reliability of next generation sequencing data.
Scroll Up
Scroll Down
Skyscraper Banner
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv